284 related articles for article (PubMed ID: 30084011)
1. Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016.
Tzankov A; Kremer M; Leguit R; Orazi A; van der Walt J; Gianelli U; Hebeda KM
Ann Hematol; 2018 Nov; 97(11):2117-2128. PubMed ID: 30084011
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow : Summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016.
Tzankov A; Hebeda K; Kremer M; Leguit R; Orazi A; van der Walt J; Gianelli U
Ann Hematol; 2017 May; 96(5):765-777. PubMed ID: 28191591
[TBL] [Abstract][Full Text] [Related]
3. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
Haroche J; Abla O
Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
[TBL] [Abstract][Full Text] [Related]
4. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
Allen CE; Parsons DW
Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
[TBL] [Abstract][Full Text] [Related]
5. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
[TBL] [Abstract][Full Text] [Related]
6. [Histiocytic diseases in childhood and adolescence].
Vokuhl C; Oschlies I; Klapper W; Leuschner I
Pathologe; 2015 Sep; 36(5):443-50. PubMed ID: 26292932
[TBL] [Abstract][Full Text] [Related]
7. Rare diseases of bone: Erdheim-Chester and Rosai-Dorfman non-Langerhans cell histiocytoses.
Mavrogenis AF; Igoumenou VG; Antoniadou T; Megaloikonomos PD; Agrogiannis G; Foukas P; Papageorgiou SG
EFORT Open Rev; 2018 Jun; 3(6):381-390. PubMed ID: 30034819
[TBL] [Abstract][Full Text] [Related]
8. Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.
Facchetti F; Pileri SA; Lorenzi L; Tabanelli V; Rimsza L; Pittaluga S; Dirnhofer S; Copie-Bergman C; de Leval L; Rosenwald A; Wotherspoon A; Fend F
Virchows Arch; 2017 Oct; 471(4):467-489. PubMed ID: 28695297
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.
Kemps PG; Hebeda KM; Pals ST; Verdijk RM; Lam KH; Bruggink AH; de Lil HS; Ruiterkamp B; de Heer K; van Laar JA; Valk PJ; Mutsaers P; Levin MD; Hogendoorn PC; van Halteren AG
J Pathol Clin Res; 2021 Jan; 7(1):10-26. PubMed ID: 32852896
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
[TBL] [Abstract][Full Text] [Related]
11. Updates on histiocytic disorders.
Vaiselbuh SR; Bryceson YT; Allen CE; Whitlock JA; Abla O
Pediatr Blood Cancer; 2014 Jul; 61(7):1329-35. PubMed ID: 24610771
[TBL] [Abstract][Full Text] [Related]
12. Langerhans cell histiocytosis: Version 2021.
Gulati N; Allen CE
Hematol Oncol; 2021 Jun; 39 Suppl 1(Suppl 1):15-23. PubMed ID: 34105821
[TBL] [Abstract][Full Text] [Related]
13. Histiocytic disorders.
McClain KL; Bigenwald C; Collin M; Haroche J; Marsh RA; Merad M; Picarsic J; Ribeiro KB; Allen CE
Nat Rev Dis Primers; 2021 Oct; 7(1):73. PubMed ID: 34620874
[TBL] [Abstract][Full Text] [Related]
14. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
15. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
16. CNS Erdheim-Chester Disease: A Challenge to Diagnose.
Pan Z; Kleinschmidt-DeMasters BK
J Neuropathol Exp Neurol; 2017 Dec; 76(12):986-996. PubMed ID: 29096034
[TBL] [Abstract][Full Text] [Related]
17. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms.
Go H; Jeon YK; Huh J; Choi SJ; Choi YD; Cha HJ; Kim HJ; Park G; Min S; Kim JE
Histopathology; 2014 Aug; 65(2):261-72. PubMed ID: 24720374
[TBL] [Abstract][Full Text] [Related]
18. PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours.
Ungureanu IA; Cohen-Aubart F; Héritier S; Haroche J; Donadieu J; Emile JF
Histopathology; 2023 Aug; 83(2):320-325. PubMed ID: 37012662
[TBL] [Abstract][Full Text] [Related]
19. Descriptive Analysis of Histiocytic and Dendritic Cell Neoplasms: A Single-Institution Experience.
Kim HM; Yang WI; Lyu CJ; Hahn SM; Yoon SO
Yonsei Med J; 2020 Sep; 61(9):774-779. PubMed ID: 32882761
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
Geerlinks AV; Abla O
Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
